
Alzinova Investor Relations Material
Latest events

Study Result
Alzinova
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Alzinova
Access all reports
Alzinova AB is a Swedish biotechnology company focused on developing treatments for Alzheimer's disease. The company's lead product is ALZ-101, a vaccine designed to target toxic oligomers of amyloid-beta, which are implicated in the progression of Alzheimer's. ALZ-101 has completed part A of its phase 1b clinical trial and continues to progress through clinical development. Alzinova is also working on ALZ-201, a monoclonal antibody that neutralizes these toxic oligomers, with a humanized version in early clinical trials. The company is headquartered in Mölndal, Sweden, and its shares are listed on the Stockholm Stock Exchange.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
ALZ
Country
🇸🇪 Sweden